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The pathogenesis of arterial thrombotic disease involves multiple
genetic and environmental factors related to atherosclerosis and throm-
bosis. Acute thrombosis at the site of a ruptured, lipid-rich atheroscle-
rotic plaque is the usual precipitating event in the transition from stable
or subclinical atherosclerotic disease to acute myocardial infarction
(MI), stroke, or peripheral arterial occlusion (1). Pathologie studies of
coronary arteries in acute MI suggest that the acute thrombosis likely
involves activation of both platelets and the coagulation System.
Following atherosclerotic plaque rupture, platelets initially adhere to
exposed subendothelial von Willebrand factor (vWF) and Collagen
through the glycoprotein Ib/IX receptor complex and the glycoprotein
la/IIa receptor complex, respectively. The attachment of platelets to the
vascular subendothelium (platelet adhesion) induces a series of intra-
cellular signaling events that result in platelet activation. The binding of
fibrinogen and vWF to the conformationally active form of the glyco-
protein Hb/IIIa receptor results in platelet cohesion or aggregation, and
further propagation of the platelet thrombus, Plaque rupture also results
in exposure of subendothelial tissue factor, which initiales the coagula-
tion cascade, and leads to the generation of thrombin and formation of
a fibrin clot. While arterial thrombi traditionally are considered to be
composed predominantly of platelets, accumulating evidence suggests
that certain arterial thrombotic disorders (e.g., transmural or "Q-wave"
MI) are associated with greater activation of the coagulation system,
which results in occlusive thrombi that are relatively rieh in fibrin (2).^
Prevention of arterial thrombotic diseases, such äs myocardial in-
farction and ischemic stroke, has focused on identification and mod-
ification of traditional cardiovascular risk factors, such äs Smoking,
hyperlipidemia, hypertension, and obesity, that are related: to athero-
sclerosis. However, approximately 30% of MI occur in individuals
without traditional cardiovascular risk factors (3). Since antithrombotic
agents such äs aspirin have been shown to be beneficial in primary and
secondary prevention of arterial thrombosis (4), attention has shifted in
recent years to the characterization and evaluation of novel phenotypic
markers of cardiovascular disease, involving lipoprotein metabolism,
the coagulation and fibrinolytic Systems, and inflammation (5, 6). In
addition, the identification of molecular variants within the genes en-
coding proteins involved in the pathogenesis of thrombosis has led to
their evaluation äs genetic ^usceptibility markers in epidemiologic
studies of arterial thrombotic disease. In this review, we briefly discuss
some general issues related to the studies that examine the associations -
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of both genetic susccpiibiliiy markers and inlcrmcdiaic hemostadcffc :.J
notypes with arterial Ihroinhotic disease. \Ve then review thet
pertaining to the roie of specilic genetic markers and hemostaticpjfcjji1!
types in arterial thromhosis.
General Issues Related to Study Design and
Interpretation of Results
Case-control und cross-scctional studies assess the rclaticmlip.'p
between phenotjpic markers (c.ü., plasiua coagulation facffif fe|jd$j
and the occurrence of arterial thrombutic disease. However;!
studies cannot esiablish a temporal order, und thercforecaoaote
the possibility thal a hemostalic phenotype is a c
disorder (e.g., due to aecompanying tissue injur>' or in
Even in prospectivc cohort sludics, the obscrved associatiöwi
confounded by subclinical atherosclerosis. which may <
both the hemostalic phenoiypes äs well äs the clinical ι
addition, plasma Icvels öl' hcmosuitic fuclors are sometimesc
with each other and-also are inlluenced by other<
factors (e.g., obesily, hyperlipidemia, smoking), that may tatet
found an apparenl relaiionship betwcen the hemostatic τΰαΛχίΛάΐ^Ά
of disease. Forthcsc rcasons, ine most convincing evidenceofae
relationship between a hemostatic phcnolypc and the ι
arterial thrombotic disease is inicrred from clinical
strate that alterin!! l he phenotype (e.g., lowering
hemostatic factor) reduces disease.
Another means of circiiinventing somc of the spurious (
that can result from Ihc use of inlermediate hemostatic
to analyze genetic variants that are known to be related tof
Variation. T h e advamage o f studying genetic varianls i s t ^
"fixed at birth", and thcrel'ore clearly preccde disease .onsetnijWj!^
confounded by oiher behavioral and environmental (
factors or subclinical atherosdcrosis. However, raolecutar fl
ologic studies evaluaiing potential genetic susce
their own set of limiuuions. and diftcrent studies
genetic marker ollen yield conflicting results. Con
among studies is liampcred by differences in sti
terisücs of case paiiems and control subjecls, Variation ofl
quencies among dift'erent populations, äs well äs ihe
heterogeneityof Ihe clinical endpoinisof coronary heart
and peripheral anerial occlusion. These complex
volve theieffect^ of multiple genes interacting wilhthe*Wj!
The effect of any single «enetic susceplibility factor riffjgj
thrombotic disease is likely lo hc rnodest, but may
importance in the presence of udditional genetic *.̂
exposures (i.e., gene-gene or gene-cnvironment i
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Äabetween a putative genctic suscepiibiliiy marker and arte-
pdisease may only he dcmoiisirablc wilhin a certain sub-
ι As;a result, large sample si/cs ma\ be ro(|uired to demon-
• stable esümaie of el'fcct. pariicularly for alleles or
; tlial arc uncommon within l ho population. >
ib'ootsnbject to conl'ouriding by olhcr behavioral and envi-
il risk factors, populalion siudics of «eneiic variants are subject
> by ethnicily, i.e.. population admixlure or "population
i". Thus, a spurious associalion may arise if the frequency
c.raarker and the frcquency öl anerial tlirombolic disease
»jccording to genetic anccstry. Thi.i is inosi likely to be the
jljtbuically hetcrogencous populalions, and tan be accounted for
i that asscss genetic linkage äs well äs association.
; reason for a positive association in some studies but
i is thal the genetic marker of inierest is not directly in-
idisease susceptibiliiy. bul radier is in linkage disequilibrium
Ifteactual causalive mutation locaied in the sanic gene or another
y. Depending on the populalion hisiory and the recombina-
ilinction, the genetie marker may be associatcd with the causative
i in some populalions bul not in olliers. Therefore, it is prefer-
iioassess genetic markers that. are wcll-characicri/ed with respect
fe ftfflctional consequences of the molecular defeci and that con-
tSgnificantly to phenotypic Variation ui i l i in Ihe population.
ι Factors
Factor VII
FactorVII is a vitamin-K dependent coagulation protein, which
upon activation, binds to tissue factor present in damaged vascular sub-
endothelium and initiales coagulation. In Ihe Northwick Park Heart
Study, a prospective sludy of over 1,300 middle-aged men, plasma
factor, VII aclivity levels were associaled with fatal, but not non-fatal,
ischemic heart disease (20). However, seveVal subsequent prospective
studies have failed to confirm Ihe associalion between faclor VII levels
and risk of coronary heart disease (21-23). Factor VII is also unrelated
to risk of venous Ihrombotic disease (24). Plasma factor VII levels are
determined by multiple environmental faclors, including age, gender,
body mass index, dielary fal, and triglyceride level (25). In addilion,
several intragenic faclor VII polymorphisms which influence plasma
factor VII levels have been described. These include an Arg353GIn
Substitution that is associated with decreased factor VII secretion
in vitro and lower factor VII levels (26). An Italian case-control sludy
of youn'g adulls wilh familial MI observed an inverse associalion wilh
homozygosity of Ihe faclor VII Gln353 allele (OR = 0.08, 95% CI =
0.01-0.9) (27). In conlrasl, several olher case-control studies involving
either young men (28) or a broader age ränge (29-31) found no associ-
alion belween Ihe Arg353Gln polymorphism and risk of MI or stroke.
Thus; the evidence to date does not support faclor VII at eilher the
phenotypic or genotypic level äs an importanl risk factor for arterial
Ihrombotic disease.
i|!B:fibrinogen levels have been consisieniK ancf independenlly
"l.an increased risk öl' MI and Mroke in prospective
idiapparently hcallhy persons and paiienis with preexisting
:disease (7-9). Subjccts with plasma fibrinogen levels
t tertile have ~2-fold increased risk compared lo Ihöse in
ftftätile. Fibrinogen may conlribuie lo arterial thrombotic
|iaanurnber of mechanisms. including increased fibrin forma-
ia:viscosiiy, platelel aggregaiion, and \ascularendolhelial
imuscle proliferalion (7). On tlie olher band, fibrinogen is an
: reactant, and the associalion of clevatcd fibrinogen and
W protein levels wilh risk of arterial thrombolic disease sug-
jl'diatthe inflammation thal acconipanies alherosclcrosis may con-
ito increased fibrinogen levels (10). Plasma fibrinogen levels are
r correlated with olher cardiovascular risk tactors, such äs
, diabetes, and cslrogens (7.11). Be/afi brate, an agent that
sboth.fibrinogcn-lowcring and lipid-modilying properties, was
l with an overall rcduction ofarterial thrombotic events in
HfClinical trial of palients with coronary heart disease (12).
ι fibrinogen is composed of 3 pairs of pol\ peplide chains, et,
i encoded by 3 separale genes clusiered on chromosome 4q.
S.Öie synthesis of the fibrinogen ß-chain is raie-limiting (13),
i ß-chain polymnrphisnis have been associaled wilh inter-
R( Variation in plasma fibrinogen levels. The 455 G/A substi-
i the promoler regiori of ι he fibrinogen ß-chain has been
texlensivcly. The -455A allele is present in about 20% of
, who have ~l()9r higher fibrinogen level> compared to
ι the GG genotypc (14). The relaiionship between the -455
(finogcn variant and risk of anerial thrombolic disease is
il. with sorne case-eonirol studies obsemng an association
fc'and other large siudies finding no associntion 118,19). These
nt finding cast doubl on ;i direct cause-and-efl'ect relalion-
wccn llbrinoüen le\els and anerial Ihrombotic disorders.
Factor VIII and von Willebrand Factor
Increased plasma levels of faclor VIII aclivily, von Willebrand fac-
lor (vWF) anligen, and vWF aclivity have been associated with incident
falal and non-falal arterial thrombotic events in prospective siudies
involving heallhy middle-aged (22,23,32,33) and elderly (34) popula-
tions. In some studies, the associations were independent of other
cardiovascular risk factors. In most prospective studies of patients
with underlying atherosclerolic disease, vWF levels have been indepen-
dently associated wilh risk of acule Ihrombotic events (10, 35, 36).
Factor VIII and vWF circulate äs a complex, and plasma levels of these
two factors are highly correlated wilh each olher. Thus, elevated fac-
tor VIII/vWF levels may be either a marker of atherosclerosis (i.e.,
endothelial dysfunction and vascular injury) or contribute directly lo
fibrin formation (factor VIII) or shear-induced platelet adhesion and
aggregaiion (vWF). The demonslralion lhat congenilal factor VIII defi-
ciency.is associated wilh decreased mortalily from ischemic heart dis-
ease (37, 38), äs well äs the association of elevated factor VIII levels
with venous thrombolic disease (39), support the hypothesis of a direct
effecl of faclor VIII concenlration on Ihe occurrence of thrombolic
events. Factor VIII levels are also influenced by ABO blood group, and
individuals with blood group non-0 have both higher factor VIII levels
and higher incidence of coronary heart disease compared to individuals
with blood group 0 (32, 40). Further evaluation of factor VIII and
cardiovascular risk awaits elucidalion of other genetic delerminanls of
increased faclor VIII levels (41).
Factor XIII
Faclor XIII is a Iransglulaminase lhal forms covalenl bonds between
adjacent fibrin monomers, and Ihus slabilizes a fibrin clol. Factor XIII
circulates äs a zymogen composed of 2 catalytic A subunits and 2 car-
rier B subunits. Thrombin cleavage of a 37-amino-acid N-terminal
peptide results in activation of the catalytic subunit. A Val34Leu poly-
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moφhisnι o l ' lhe c a i a l y i i c M.ibi ini i i.·« locaied 3 a inino acid roiidues I r o i i i
the thrombiii olca\ age site. and ihe los·« coinmon l.eu34 a l lc le h;i> Iven
associated u i i h incroascd plasma lacior X I I I ac i i\ i ty le\ds (42, 131.
Paradoxically. sevcral rcccnt smdies suggosi Ihm l ho "high a c i i \ i i y "
Leu34 allclo may he associalod w i i l i a decreased ri.ik öl' MI (44. 45i.
ischemic ancrial siroko (46). and vonons ihromboiic disoasc (47l, äs
well äs an incrcascd risk öl' hemorrhauic siroke i4Si. Tho niochanism
for the apparent aniiihronihoiic effccl οΓ ι ΐ ι ο lacior XI11 Vall .L-u34
Substitution may involve an increased raie of convorsion οΓ lacior XIII
to activalcd lacior X I I I by thrombin lhai resuli* in an aliered cross-
linkedfibrin clol simciure (49l.
Levels of oilicr (.'»amiltitiini l'aciim
Recenily. clcvaicd levels of lacior \'. bin not i'aclor X or proihrorn-
bin, were associated w i lh occurrence οΓ Ml aller adjusting l'or oihcr risk
factors (SOi. liocausc ol ' the reirospeclive naiure o f l h i . s siudy, onc can
not distiniiuish whoihor increased lacior V acii v i iy is a caiise ralhcrihan
a consequence of Ml. To our knowlcdgc. Ihc a>socialions of lovcls of
coagulation laciors XI. X. and IX. V. and proihronibin with arlerial
thrombotic disease have noi heen assc.ised in pro^peciive Mudics.
Inherited Thrombophilic Disorders
Protein (', Protein S. Antiihroinhin Deßriency
It is \\cll-osiahlishod lhai congenital det'iciencics of protein (.'.. pro-
tein S, and anliilirombin are associalecl wilh an increased ri.ik of venous
thrombotic disease. \Vhelhcr congeniial deficiencies of thesc naturally-
occurrin» coagulalion inhibitors are associalecl \\iih increaied risk of
arterial thromhoiic di.scasc is less clear öl. 52 i. In a pooled analysis
of 8 small series of anorial cerebral infarclion in predominanily young
patients i n = 3l 1 1. deficiencies of proiein S. proioin ('. and anlithrom-
bin were noied in 1 1.')' i. 2. 2' i. and 2.2'.'·; of cases. respecli\d\ (53 1.
However. in niaiiy -of ilu.se siudies. inicrpretalion of rcsuhs is limited
due to small mimhcr< of subjeeis. lack of controk lack of follou-up or
family siudic.i lo docinnenl inherilcd v>. acquiroil ddicicncy. and pop-
ulation adini.Miire. Morc recenl smdies of unselecied young adiills with
acute cerebral ischemia suggoit lhai aciile. iransioni or acquired defi-
ciencies of the naiurally-occurring anticoa.suilimis are noi iincommon.
but that iruo congoniial deticiencies are rare (54-.Ϊ6). Several recent
pediatric SCIUN siiajjcsi ι hat prolein C" or proioin S deficiency may be
present in äs many a*. 5-15'ί ofchildren wilh ischemic siroke (57-591.
However. in Mime case> inie con«enilal deficiency has not been clcarly
documeniod. and oilior |»xliairic siudies ha\c not confirmed these asso-
dations 1 60. 6l l. Taken logether. l ho evidena: suggests ι hat deficien-
cies of natural anticoaüulanls are l ikoly 10 be assoeiaied wilh arlerial
thromboiic disease. panicularly in very younu indiviüuals with acule
cerebral ischemia. Ho\vc\er. since ihe prevalences of theso deficicMicies
are low even amon;j younc palienls. ihey accouni for a small proporlion
of cases.
ActivatetI Protein (' Kevxmnre and l-'ucior \ ' Leiden
Resistance lo ihe anticoaguluni effect of acli\ated prolein C! is mosi
commonlj due lo a nucleoiide (Ί 1 69 1 Λ nunaiion in the szene encodinu
factor V (hat resulis in an .-\rs5()6(iln iiuiuiiion (factor V Leiden), "l'his
mutation occurs al Ihe i n i t i a l acli\aled protein C cleava»e site w i l h i n
the factor Va heavy chain and rc.siilis in a prothn>mbotic siate becaibe
of a roducod MIO of facior \'a inac i iva i ion. l-'acior V l .eiden is themojt
coiniDon iionoiio facior as.ioc.kned with risk of venous ihroinboenüxiBt;
disease, and is foinid in approximaiely 3-5'.i öl the Caucasian ρρρ&,«
·-''^
A relaiionship betwecn factor V Leiden and arlerial ihr
ease was first suggosiod by Hohn öl al. (64). who rcponed twoyöj
women lagos 33 and 34 years) with Ml and homo/ygosily forf
Gln5()6. However. nu>sl subscquenl siudies have failed to.-j
associalion boiween factor V Leiden and coronary disease on,
MI (65-71), even among patienls who dcveloped acutc coromey.'̂
dromes al a young age (72-74). In contrasl, Roscndaal et al. (
öd a higher risk of non-falal Ml among young female cariieisoi
torV Leiden (OR 2.4, 95<i Cl 1.0-5.9) lhat was particulalyü
among smokers (32-fold increased risk comparcd lo nonsi
women withoul ihe facior V muiation). In a largc. casc-controlsta
middle-aged-to-elderly Duich men, Doggen el al. (76) alsore
inercased risk of MI assoeiaied with hetcro/ygosity for factor Vi
(OR l .4:95Ύ Cl 0.8 2.2) ihai was mosi pronounced in men wjtb.oj^v
cardiovascular risk faclors. ... .yi:y$
\Vhi le facior V Leiden is noi a risk facior for ischemic sbobJll
middlo-agod lo elderly patienls. (66. 68. 71, 77), some studkti
youngor adults (<45-50 years) indicale a higher prevalenceoffkliirl
Leiden in siroke cases ihan conlrols (56), bul mosl shuwnoi
(78-80). In an Italian siudy (56). the risk of siroke associaledS
lacior V Leiden mutalion was sinniger in women Ihan men, j
smaller North American study of exclusively young womenί
association (80). In children. recent data suggesLs that i
may accouni for approximaiely 2()'.i. (if cases of is
(58-60.81).
The relaiionship beiwecn lacior V Leiden and
occlusixc disease has been examined in thrcc case-cpnöol-S
two siudies, Ihe fiequcncy of facior V Leiden carriershiJMiii
among eases. whiclns higher than the population ]
In conlrasl. a larger AuMrian siudy of 336 patients. with']
arterial occlusion and 300 conlrols observcd a similar f
facior V Leiden mulalion betwecn cases (8%) and controb(
Takcn together. ihe cumulaiive resulis of studiesexaminjflgl
tionship of facior V Leiden and incident arterial throrabotic'i
suggest lhat facior V Leiden is noi a major cardiovascülar.lill
but may assumc increased imponancc in cenain patienti
panicularly children wrih ancrial siroke and young womeiM
cardiovascular risk factors. Allernatively. the positive findingl»
only a l'ew of Ihe puhlished siudies suggesls the possibilityofi
positive associalion due lo population admixture. AddiöofHll
tion siudies involving larger numbers of subjects i
siudies lhat assess geoelic linkago will bc required to ί
issues.
Thcre is some ovidcncc lhat aclivaied proiein Cfesislaeeil
ence the risk of arlerial ihroinboiic disease even in!
factor V Leiden mutalion (85, 86). In a cross-!
men and women. carolid and feinoral artcry atherosderasBi
prevalent athero-ihromhoiic disease were associated '
response lo APC (86). In ihis study. less than 50% of tbe«
APC resislance were carriers of the factor V Leiden i
ing lhai oihcr gcnelic and environmental factors raay <
APC resislance phenolype äs well äs to Ihc riskof art«?W<
disease (86.87). I Iowever. the e\ aluation of a phenotypcr"
contexl of a cross-seclional study raises Ihe issue of *
resislance is a consequence rather Ihan a cause of ί
thrombosis.
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fG20210A Mutation
i is.the circulating precursor öl' ihronibin. which pliiys ;i
sinfibrin fonnalion and ihrombosis. A G to A iransition in
520210 »ithin ihe .V untranslaled region of ihe proihromhin
l with elcvalcd circulating prothronibin levcK, and
identified äs a risk lacior l'or venous thromboembolic
fe(88)..This mutalion is presem in about 2'i of Caucasians. (>ιιι
— i;--«increases froni Nonhcrn lo Southern F.nmpc (89).
V leiden, the rclationship bclween ihe prothrombin
fc Imitation and risk of arlerial ihronibolic (iisease is conirover-
jiiost of the published studies. ihcre was no as.iociation beiween
!0f the 202ΙΟΛ allele and risk of acuie MI or coronary
: (90-94). Whilc ihcsc rcsults suggest llial ihi; prothrombin
W is not a major risk facior for coronary hcarl discase. llic sial is ·
rof many of ihcse studies lo deiect an association \* l imhcd
flriatively Iow frequcncy of ihe imnalion in ihc gencral popula-
I pooled analysis of 1.115 palicnis and 1.888 conirols l'roin
[.Franco et al. nolcd a significani association in l he Mudies lhat
itootifioed to patients wilh MI (OR = 2.5: 95',?· CI l .5 4..?). bin no
ι in die pooled analysis of Mudies lhat iricludcd eases w i i h a
f ränge of athero-thrombolic disease (95). In the: largest single
ii'icase-control study of patienls with MI (560 paticnis under
ί70)( the prothrombin 202 1 OA allele was associalcd w i i h a
6) incrcascd risk of MI (hat incrcascd substaniially 10
e-pfesencc of tradiiional cardiovascular risk factors such äs
Jhypertension (76). Similarlv. in a small case-conirol siudv
|:<45 years old with acute MI, Roscndaal et al. reponed a
l risk of MI associatcd wilh prothrombin 202 1 ΟΛ thai
'enhanced in the presencc of smokin» or other meiabolie
of studies examining the rclalionship bciween pro-
»;"620210A and ischemic artcrial siroke in young adults (56.
dolder subjccts (90, 94) have bcen negali\ e. The exceplion is
öl sludy of 72 Italian young inen and womcn (<5() \ears
h ischemic arlerial strokc u ho did not have tradilional cardio-
rrisk factors (OR = 5.1. 95';;. CI = 1.6-16.3) (78). In a casc-
istudy of 148 pediairic palicnis. the prolhrombin 202 IOA allele
with a 5-fold increased risk of sponlaneons ischemic
oke (58), but iwo srnallcr pediairic siudies found no associa-
it,i8l). A recenl case-control study found no association of ihe
1 2021 OA allele with risk of periphcral arlerial occlusion in
f patient population (84).
i-together. the resulis of these studies suggest lhat the pro-
ΪΪ20210Α mulalion may bc associaied with a modesily in-
trisk of arterial thronibotic disease thal may as.Miine (tanicular
• in certain subgroups. such äs young wornen wilh MI or
vascular events in children.
rftecsptor Polymorphisms
nein llb/llla
itein llb/llla (integrin «nißi) is the plalelei surlace receplor
in. von \Villebrand facior (vWK). and scvcral other adhe-
ands. The glvcoprolein l i la subunil consisis of iwo common
ns,PI.A: ( I I P A - l a ) a n d ΡΙΛ' ( I I P A - l b ) . Thisdimorphism i s d u e
C niicleoiide . s i ibMilut ion i n v o l v i n g niicleoiide 1565 w i t l i i n
l2 of ihc glvcoprotein l i l a gene. and rcsiilh in a I.cu33/Pro33
subst i lut ion thal is associaied wi lh a confonnational chan.ue in die
N-ienninal disulf ide loop öl 'glwoprolcin l i la re la t ixe to ihe llbrinotien
binding sile (98). The allele l'reqiiency ol 'ihe ΙΊ.Λ: variani ranges l'roin
~l() 10 18 perceni in (..'auca^ian populatioib. ~8'·ί in African po|)i:la-
lions. and is vir iual ly abscnl in A>ian popnlaiions.
In 1996. V\'eiss et al. rcponcd lhat ihe fre(|iiency of carr\ing al Ica1·!
one copy ol'ihe ΙΊ.Λ: allele was iwice äs hish in 7l hospiuili/.ed paiienis
wi ih MI or unsiablc anüina 1 39.4'. r l compared wiih 68 lios|)iiali/ed
conirol subjecls 1 1 9. l '"t ) (OR = 2.8: 95 '·ί (Ί = l .1 6.4) (99i. \Vhen the
analys is was resiricied lo ihe subgronp of paiienis under Ihe agc of 60.
ihe relaiive risk of acnto coronarj disease associaied \v i lh Ihe I'I..N:
allele increased 10 6.2 (95'. ί (Ί = 1.8-22.4). Since ihis init ial repon.
liiere have been over 20 addilional observaiional siudies ihat have
c.xamincd ihc relaiionship bciwecn ihe ΡΙ.Λ '/ΙΊ.Χ· ' polymorphi^ni of
cKcoproiein l i l a and risk öl acnie or Mahle coronary arlerv disease.
\\hile- a leu ofihese siudies have confinned ihe a>Miciation beiween
Ihe ΙΊΛ! a l le le and increased risk of early-iMixei coronury hcan disease
(73. l (K)- 1 02). ihe m a j o r i i v have nol. The noüai i \e \iudie> include ihe
5 iinoKing al leasi 300 cases ( 1 03- 1 07 1. Iknvever. cornparison öl ihe
resulis among studies is complicaied by differences in definilion öl
coronary disease. selection of conirol siibjecis. and study de>ij;n. Thu.v
neüal ive reMilts obserxed in some siudies mi»li i he e.xpected if ihe ;ΙΛ·>Ο-
eiaiion is confined 10 younger paiients \ \ i l l i MI and/or to specific sub
jiroups. such äs womcn l l ( )2 i . eiuarcnc smoker«. (73 1. individuals wiih
pre-cxisiing coronary atherosclerosis (10h. or indi\iduals wiih addi-
lional geneiic prcdisposiiioris ί 108 1.
Of ihe published siudies ihai have asse.ssed Ihe rclalionship beiween
ΡΙ.Λ- and ischemic siroke. one (109) observcd an associaiion only
in subgroups of paiienis under ihe age öl 50 (OR ~ 1.68: 95ri CI
1.00- 2^X2 1 and in non-smokers ι OK = 137: 95'·ί (Ί 1.Ι94.74.Ι. and
anoiher only in a small subgronp of womcn (n = 18) w h o wcre w h i i e
and had an identillable ciiology ( l 10). In contra.·.!. IWO other siudies
involving a broaderage ränge ol'both men and womcn ( I I I . 112). and
a siudj of male physicians ( 1 06) found no a>sociation beiween ihe l'l .Λ"
variant and risk of ischemic siroke.
The assessmem ol'ihe relaiionship between ihe l'l.·'1 geneiic var iani
ofgKcopmiein l i l a and risk of arlerial ihronibolic disease is aNo ham-
pcred by the lack of a clearlv del'ined el'feci on plaielet fui ic i ioi i . \\ h i l e
some studies ha\e deinonsiraicd Ihai Pl/^-posilivc plaielcls displav in-
creased in \ i i r o platclcl reaciiviiy compared to ΡΙΛ'-negaiive plaielets
(1 13. 1 14). oihers have not ( 1 15. 1 16). The associaiion beiween Pl..':
and an increased ihronibolic icndcncy is also tupponcd by experiments
usin» stähle eell lines overexpressin« ihe ΙΊ.υ and Ρ Ι Λ · polxmorphic
fornis ol'glvcoproicin l l b / l l l a ( 1 1 7i. äs well äs a recenl auiopsy sludy in
which the presencc ol'ihe ΡΙ.Λ· allek· was associaied w i l h an increased
l'rec|ueucy (>f aeuie coronary Ihrombo.iis and complicaied aiherosclerot-
ic plaques in men wilh fatal M i d i 8).
In summary. both ihe clinical and experimcnial data assessing ihe
role ol'ihe PLC variani of ghcoprotein l i la in arterial Ihronibolic dis-
ease have yiclded conlliciing resulis. Addil ional moleculargcneiic and
l'unciional analys is of ihe plalelei glycoproiein l l b / l l l a recepior. äs well
äs \iudics i uvo l v i ng larger nnnibcr> of subjeeis that allow straiilicalion
by 01 her cardiovascular risk l'aclors. w i l l be recjuired lo resolve ihese
issues.
Iw'llu
(ilycoproiein la / l l a l in iegr in < > - ß ! is ihe major plalelei Collagen
rcceptor. and is rcsponsiblc l'or plalelei adhorence 10 exposed vascular
.siibendoihelinm. Several .-.ingle niicleoiide polymorphisins w i i h i n ihe
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glycoprotem la (a, integrin) subunit of the glycoprotein ia/IIa receptor
have been described. T wo silent single nucleotide polymorphisms.
C807T and G873A are in complete linkage disequilibrium with each
other, äs well äs with several other single nucleotide polymorphisms
located in the adjoining introns ( l 19. 120). Among normal individuals.
there is a 5-10 fold Variation in the surface level of glycoprotein Ia/IIa
that correlates with collagen-induced platelet adhesion and aggregation
in vitro. The nucleotide 807T variant of glycoprotein Ja is associated
with increased platelet glycoprotein Ia/IIa receptor levels and in-
creased collagen-induced platelet adhesion compared to the 807C allele
(l 19-121). The mechanism of the association between the 807T allele
and increased receptor density is unknown. The 807T allele may be
linked to another polymorphism within the glycoprotein la gene in-
volving a regulatory element that controls gene transcription levels or
mRNA stability.
The prothrombotic tendency of the glycoprotein la 807T allele is
supported by four recent case-control studies. In a study of 2,237 con-
secutive German men undergoing coronary angiography, Santoso et al.
(122) reported a higher frequency of the 807T allele in individuals who
had suffered an MI compared to those without MI (OR 1.57; 95% CI
1.14-2.13) that was most pronounced in obese men under the age of
49 (OR 4.92; 95% CI 1.71-14.2). In a smaller case-control study,
Moshfegh et al. reported a 3-fold increased risk of MI in individuals
who carried two copies of the 807T allele compared to individuals who
possessed the CC or CT genotype (OR 3.3; 95% CI 1.23-8.83) (123).
Similarly, the 807T allele was associated with a 2-3 fold increased risk
of ischemic stroke in men under the age of 50 (124) and women under
the age of 45 (125). In contrast to these 4 positive studies, Croft et al.
reported no association between glycoprotein C807T and risk of MI.
either overall (OR 0.88. 95% CI 0.74-1.05). in younger individuals, or
in subgroups defined by other risk factors (126). Corral et al. also re-
ported no association between the 807T allele and risk of either acute
coronary heart disease or ischemic stroke in a middle-aged to elderly
study population (121). Furthermore, it should be noted that the fre-
quency of 807TT homozygotes among the control group of one of the
positive studies (5.6%) was considerably lower than other published
population studies (123). In summary, preliminary results suggest that
the 807T variant of glycoprotein la may be a genetic risk factor for
early-onset arterial thrombotic disease, but further studies involving
larger numbers of subjects, äs well äs further characterization of the
mechanism responsible for increased receptor levels, are required to
settle this issue.
Glycoprotein Ib/IX
Glycoprotein Ib/IX receptor is the major platelet receptor for von
Willebrand factor. Two polymorphisms that affect the amino acid se-
quence of the glycoprotein Ib heavy chain (glycoprotein Iba) have been
described. The first, an ACG to ATG Substitution at codon 145, results
in a Thr/Met dimorphism that is responsible for the human platelet anti-
gen (HPA)-2 System. The second is a size polymorphism that results
from a variable number of tandem repeats (VNTR) of a 13-amino-acid
sequence (Ser399-Thr411) that is present in either one (D), two (C),
three (B), or four (A) copies (127). The HPA-2 and VNTR polymor-
phisms are in strong linkage disequilibrium with each other. The
HPA-2 Thrl45Met dimorphism results in a protein conformational
change in a region adjacent to the vWF binding region of glycopro-
tein Iba, but an effect on in vitro platelet function or von Willbebrand
factor binding has not been demonstrated (128, 129). The VNTR poly-
morphism involves the macroglycopeptide region of glycoprotein Iba,
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with the addition of each repeat resulting in an increased distan^·
between the ligand binding region and the platelet surface. While it hj.
been hypothesized that this distance Variation may affect platelet \IK
ceptibility to shear-induced activation (127), this has yet to be demon-
strated experimentally.
Despite the lack of an associated prothrombotic phenotype, se\erai
case-control studies have noted a 2-3 fold increased risk of coro-
nary heart disease or stroke associated with the Met 145 (HPA-2bi or
VNTR-B allele. particularly in younger patients (130-132). In contra^
Ardissino et al. did not find an association between the HPA-2 pol\-
morphism and premature MI in a case-control study involvins pre-
dominantly men (73). Two other studies did not observe an association
between HPA-2 or VNTR genotypes and risk of ischemic stroke in
older patient populations (109, 112).
Other Hemostatic Factors
Fibrinohtic Svstein
The fibrinolytic System consists of the circulating proen/\mc
plasminogen, which is converted to plasmin by the plasminogen acuu
tors, tPA and urokinase. Plasminogen activator inhibitor-1 ( P A 1 - 1 1 1 > j
major inhibitor of the fibrinolytic system, and is synthesi/ed h\ j
variety of cell types, including platelets, endothelial cells. and \avcuL·
smooth muscle cells. Data from several prospective studies indicaie r
association between plasma levels of various fibrinolytic markers 11 c
tPA antigen, PAI-1 activity and antigen levels, and fibrin degradamM·
products) and risk of arterial thrombotic disease (133-137). Thi· pre*
ence of increased levels of PAI-1 mRNA in atherosclerotic plaqui·
(138) and the association of elevated plasma PAI-1 levels u i th ̂
clinical atherosclerosis (139) also suggest a role for impaired fihnno!»
sis in the occurrence of athero-thrombotic disease. However. ihh ro;
is complex; Inhibition of fibrinolysis may promote thrombosi·,. h.<
also may inhibit matrix metalloendopeptidase activation and xascui;·
smooth muscle proliferation. which may alter atherosderolic plaqu:
stability (140).
The Interpretation of cardiovascular epidemiologic Studie1· < > t fit".'
olytic markers is complicated by several other factors. Plasma ιΡ·\ jn1
gen and PAI-1 activity levels are highly correlated. m pari hecaux.· '*
tPA antigen assay measures both free tPA and tPA complcvii ·
PAI-1. which increases in patients with high PAI-1 l e \ e l s du.· i··*
layed clearance (141). Measurement and Interpretation öl pb"··
PAI-1 activity levels are particularly problematic due to dmmai >-·'»
tion, spontaneous transformation of PAI-1 to an inaclhe or 'sj'Z'
form at neutral pH, and the potential for release of PAI-1 from pbicsf·
these necessitate special measures during blood collection and Μ"Ϊ'
processing (142). PAI-1 is also an acute phase reactant. and cirniU'·?··
levels are influenced by a number of hormones and c>tokinev 114"· Λ
creased PAI-1 levels are also correlated with obesit\. hNpenrwfe-"--·
and hypertriglyceridemia, (i.e., the "insulin resistancc s)mlf«
Thus, in most epidemiologic studies, the association between Γ V
tPA levels and risk of arterial thrombotic disease ma\ ho c> >«<''·-"'*''
by these other cardiovascular risk factors.
The 4G allele of the 4G/5G polymorphism located » n h i n :rc ̂
moter region of the PAI-1 gene has been associated w ü h m·"*'^
cytokine-induced gene transcription in vitro (143) due ditlerenta · *·
ing of a transcriptional repressor (144), and increased pl^nu l
levels m most studies (140). While several case-conirolxluJli*'^''
demonstrated an increased risk of MI or coronan arten dM·^ *w
Reiner et al.: Hemostatic Risk Faclors and Aricnal Thromholic Disease
l allele (144-146), these findings have not been con- Lipoprotein (a)
fi'.*W>
' , m xjieral larger studies (147-149). A meta-analysis of nine
'". -vh:! mcluded 1.521 cases and 2,120 controls indicated an over-
<S'*-fcih increased risk of MI associated with the 40 allele (OR l .23,
1' Π |'|t4-l.45) (150). However, the increased risk was confined to
*. ,-ί-wtJp of case-control studies in which both cases and controls
trom "high-risk" populations.
a sulfur-containing amino acid that is formed äs an
Λ compound during methionine metabolism. Congenital
>, ,·-.ν> ̂ timiria. a rare autosomal recessive metabolic disorder, is asso-
„' min *ery high levels (>100μηιο1/ί) of fasting plasma total
Sl r. o>ieini. and is often accompanied by premature thrombotic
jiv·-^' imohing the coronary, cerebral, and peripheral arteries. Mild
ι.,-rtiiniocweinemia (i.e., >15μηιο1/ί) is not uncommon in the
•,',:r.u popukition. and is associated with a variety of acquired and
:'i\ uiors. including increasing age, male sex, cigarette smoking,
r.ivaK'i'iMiniption of nutritional factors (folate, vitamin B6, vitamin
» . , rcnal failure. and heterozygous deficiencies of enzymes involved
,; ΜΙΗΚΛsteine metabolism (151, 152). The adverse effects of
sfvoivteine include vascular endothelial injury, smooth muscle
yiitiraiion. oxidation of low-density lipoprotein cholesterol, and in-
Aition of a prothrombotic vascular endothelial microenvironment
,<l. 152).
>iincc the very high levels of plasma homocysteine that accompany
iejenital homocystinuria are strongly related to risk of arterial throm-
\& disease, some degree of association with mildly elevated levels i.s
tut plausible. There have been a number of case-control and cross-
ctiunal studies that indicate that mild hyperhomocysteinemia is asso-
ίαά ttith an increased risk of coronary heart disease, cerebrovascular
käse, and peripheral vascular disease (153-155). However, it should
*soted that homocysteine levels may increase following acute arte-
•al thrombosis (156, 157), which complicates the Interpretation of
in which levels are measured retrospectively. Prospective
assessmg the risk of arterial thrombotic disease associated with
»oied homocysteine levels have yielded mixed results with most
showing a weak or no association (154. 155). The strengest
\\iaiions have tended to occur in studies involving subjects with
wxisling cardiovascular disease. This raises the issue of whether the
wied homocysteine levels are a consequence rather than a cause of
Winical atherosclerosis.
•Mild hyperhomocysteinemia has been associated with a thermola-
wriant of MTHFR that is due to a C to T transition at nucleotide
Homozygosity for the C677T MTHFR variant is present in 5% fo
ofCaucasians. A recent meta-analysis of 23 case-control studies
ling over 12,000 subjects concluded that homozygosity for the
'labile MTHFR variant is not associated with risk of cardiovas-
disease (158). This absence of an association raises doubt about
•'role of mild hyperhomocysteinemia äs a cause of arterial throm-
: disease. However. based on the association of MTHFR and
κΐίίι Dcysteine levels, the predicted relative risk of the thermolabile
genotype is small (possibly no more than a 20-percent risk
,· pr*. öse), and even a meta-analysis may have insufficient power to
Ö a risk of this magnitude. Ongoing randomized clinical trials of
and B vitamin supplementation to reduce plasma homocysteine
Should provide more definitive answers to the public health
(ns surroundins homocvsteine and risk of athero-thrombotic
Lp(a) is a complex serum lipoprotein composed of an LDL particle
linked by its surface apolipoprotein (apo) B-100 via a disulfide bond to
a unique and highly polymorphic glycoprotein, apo(a) (159). Apo(a)
shares extensive structural homology with plasminogen, and consists of
a ηοπ-functional serine protease domain, a variable number of multiple
repeats of kringle IV, and a single copy of kringle V. The variable
number of kringle IV repeats is due to varying number of copies within
the apo(a) gene. and results in at least 35 different molecular weight
isoforms.
Plasma Lp(a) levels are largely genetically determined (160). and
vary inversely with apo(a) isoform size. Levels increase in patients with
renal disease, and are lower m white populations compared to African
Americans (161). In contrast to plasma LDL levels, Lp(a) levels are
unaffected by diet. physical activity, and most lipid-lowenng agents.
On the other band, estrogen replacement therapy and high-dose niacin
can lower plasma Lp(a) levels.
Experimental evidence suggests that Lp(a) may contribute to the
occurrence of arterial thrombotic disease through effects on both
atherosclerosis and thrombosis (159). Oxidized Lp(a) can be internal-
ized by macrophages and contribute to delivery of cholesterol to sites
of vessel injury. Because of its structural similarity to plasminogen.
Lp(a) inhibits plasminogen binding to fibrin and endothelial cells
(162). and thereby inteiferes with fibrinolysis and promotes thrombosis
(163). Lp(a) accumulates in atherosclerotic lesions, and has been impli-
cated in the progression of coronary atherosclerosis (164). Lp(a) may
also impair endothelial function and induce smooth muscle prolifera-
tion.
Despite these experimental data. clinical data supporting the
role of Lp(a) äs a cardiovascular risk factor are controversial.
A number of studies have shown an association between elevated
Lp(a) levels and mcreased risk of coronary. cerebrovascular, and
peripheral arterial disease (161, 165, 166). However, like homo-
cysteine, Lp(a) levels increase following an acute thrombotic event.
Thus. retrospective .studies may not be able to discern whether
elevated Lp(a) levels are the cause or consequence of cardiovascular
disease, and prospective studies have yielded conflicting results
(167-174). Based on the cumulative epidemiologic data. if an associa-
tion between Lp(a) levels and cardiovascular exists, the effect is
likely to be small and confined to a small proportion of the popula-
tion with the very highest serum levels (175), onset at a young age
(170) or those with additional dyslipidemias (167, 174, 176. 177).
Further evaluation of the significance of apo(a) isoform size on the
occurrence of athero-thrombotic disease (171. 177) äs well äs other
genetic mechanisms that underlie Lp(a) heterogeneity (178) may lead
to improvements in the use of Lp(a) äs a determinant of cardiovascular
risk.
Thrombomodulin
Thrombomodulin is an endothelial cell surface receptor for thrombin
that functions äs an anticoagulant by greatly accelerating thrombin-
induced activation of protein C. A soluble, truncated form of thrombo-
modulin circulates in plasma, but its significance is unknown. In a large
prospective case-cohort study. decreased plasma thrombomodulin
levels were associated with an increased risk of MI (179). Some reports
have suggested that several rare polymorphisms within the thrombo-
modulin promoter and coding sequence may be related to risk of MI
(180-182).
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Recommendations for Screening
Despite the proliferation of epidemiologic studies. increased fibrino-
gen level remains the only hemostatic biomarker that has been clearly
identified äs a risk factor for arterial thrombotic disease. And even for
fibrinogen one may question the causality of the association. The deci-
sion whether to perform screening for a hemostatic marker, however,
should be based on whether screening offers a cost-effective way of
identifying individuals who would benefit from treatment. Therefore,
screening of plasma fibrinogen is generally not advocated because
levels are favorably affected by modification of other risk factors (e. g.,
smoking cessation, exercise, and post-menopausal hormone replace-
ment therapy) and because a beneficial effect of lowering fibrinogen
level on cardiovascular risk has yet to be demonstrated. There is some
epidemiologic and biologic evidence that elevated plasma levels of
factor VIII. homocysteine, and Lp(a). äs well äs several genetic hemo-
static variants (factor V Leiden, factor XIII Leu34, prothrombin
G20210A, the PLA: variant of glycoprotein lila, and glycoprotein la
807T) are related to the occurrence of arterial thrombosis. However,
there is currently no evidence that screening for any of the above hemo-
static markers either within the general population or among subgroups,
such äs individuals who develop arterial thrombotic disease at a young
age, would have any prognostic or therapeutic consequences. Several
inherited conditions associated with venous thrombosis (deficiencies of
protein C. protein S or antithrombin, factor V Leiden, and prothrombin
G20210A) are not äs important in the overall occurrence of arterial
thrombosis. except possibly in subgroups such äs the very young or pre-
menopausal women. Thus, evaluation of these disorders in the setting
of arterial thrombosis may be considered in young patients once more
likely candidates (lipid disorders, hyperhomocystenemia, lupus anti-
coagulant/antiphospholipid antibody syndrome) have been excluded,
or in MI patients without significant coronary atherosclerosis (183). In
addition, a thrombin time and fibrinogen level should be obtained in
these young patients to exclude congenital dysfibrinogenemia, another
rare cause of both venous and arterial thrombophilia (184).
Conclusion
With the progression of the human genome project and the recent
focus on identification of inter-individual genetic Variation, the poten-
tial for evaluating the relationship between functional variants of candi-
date genes, associated prothrombotic phenotypes. and risk of arterial
thrombotic disease will greatly increase. Several guidelines for future
studies that evaluate novel hemostatic markers should be considered.
First, molecular epidemiologic studies should focus on genetic muta-
tions that are associated with clearly defined effects on hemostatic
function and that contribute significantly to inter-individual phenotypic
Variation. Second. examination of homogenous populations and pre-
cise. well-defined clinical outcomes should enhance the ability to detect
associations. For example, hereditary determination by äs yet unidenti-
fied genetic factors may be particularly important in MI that occurs at
younger ages and in women (185). Furthermore, restriction to ethnical-
ly homogeneous populations or eliciting detailed Information regarding
genetic ancestry from study subjects should minimize the problem of
false positive associations arising from population admixture. In addi-
tion, any preliminary associations observed in population-based studies
should be complemented with family-based studies that provide evi-
dence that the marker of interest is genetically linked to the disease
(186). Third, large sample sizes wil l be required to provide enough
statistical power to assess the interaction of genetic susceptibility mark-
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ers with other genetic and environmental risk factors. UndoubtedK
other candidate genes and associated functional polymoφhisms m
volved in arterial thrombotic disease will continue to be ideniiile^
Integration of knowledge involving novel hemostatic biomarkers at iht
genetic, biochemical, and clinical-epidemiologic levels should lead i,
significant developments in understanding the pathophysiology of arte
rial thrombotic disease, the assessment of cardiovascular risk, and thc
targeting of specific antithrombotic therapies to high-risk individuaN
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